SOLANA BEACH, Calif., Aug. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets Group: IMMY), a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has created a Science and Regulatory Advisory Board and that Dr. Gerald Yakatan has become the inaugural member of the newly created board. The Imprimis Science and Regulatory Advisory Board will be comprised of scientists and pharmaceutical industry thought leaders who have demonstrated a record of success in developing drugs for clearance by the US Food & Drug Administration. The mission of the Imprimis Science and Regulatory Advisory Board will be to advise Imprimis management on the future development of the patented Accudel topical drug delivery platform and to assist in the design and execution of the planned Phase 3 clinical studies for Imprimis's topical 10% ketoprofen anti-inflammatory drug called Impracor.
Imprimis Pharmaceuticals, Inc. CEO Mark L. Baum stated, "The Imprimis team welcomes Dr. Yakatan to our newly created Science and Regulatory Advisory Board. Jerry is an impressive figure in the pharmaceutical industry, experiencing success in the academic world at University of Texas, Austin where he served as a Professor and eventually as Chairman of the Pharmaceutics Department, and later in industry where in 1980 he joined Warner Lambert as Director of Pharmacokinetics and Drug Metabolism and eventually was promoted to Vice President of Product Development Worldwide. At Warner Lambert, Dr. Yakatan participated in the development of several drug products including Lopid®, Lipitor®, Eryc® Accupril®, Neurontin® and the Benadryl® cough line. In 1998, Dr. Yakatan began his tenure at Avanir Pharmaceuticals as President and Chief Executive Officer where he led the development efforts of Nuedexta and where he was responsible for the regulatory approval and commercialization of Abreva®. Dr. Yakatan is a Fellow of the American Association of Pharmaceutical Scientists and of the American College of Clinical Pharmacology."
Dr. Yakatan commented, "I have met with the Imprimis managers on several occasions and have reviewed the significant opportunity Imprimis has. I believe that my experience in participating in every step of the drug development process, including the stage that Impracor is at now, can make a difference in terms of avoiding certain trial design pitfalls, managing the trial process and ultimately presenting a relevant and compelling body of data to the FDA for approval."
Baum added, "Our Impracor upcoming trials are 'must-win' and our team has invested considerably in reviewing our existing data and designing a new trial that has the benefit of this 'rear view' analysis. We believe that Jerry's leadership and participation on our Science and Regulatory Advisory Board will provide critical guidance to our team as we approach this important project as well as future development opportunities with our patented Accudel topical drug delivery platform."
About Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. The Imprimis Pharmaceuticals, Inc. website is currently under construction and is expected to launch in August of 2012.
For More Information
Contact: Mark L. Baum
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE Imprimis Pharmaceuticals, Inc.